The Latest Breaking News from MCK

As Cardinal Health has outpaced the Dow over the past year, analysts remain bullish about the stock’s prospects.

Due to Cencora's outperformance relative to the broader S&P 500 Index, Wall Street analysts remain strongly optimistic about the stock’s outlook.

McKesson has outstripped the S&P 500 Index's rally over the past year, igniting analysts’ unflinching optimism about the healthcare stock's steadfast, upward trajectory.

McKesson has outpaced the broader market returns over the past year, and analysts remain upbeat on MCK, noting the company’s reliable growth momentum and supportive earnings outlook.

McKesson (MCK) is trading at new all-time highs and has strong technical momentum. MCK has a 100% “Buy” opinion from Barchart. Shares are up nearly 60% over the past year. Analyst sentiment is overwhelmingly positive, with multiple “Strong Buy” ratings and price targets up to $984, despite some valuation concerns....

McKesson is expected to announce its second-quarter results next month, and analysts predict a double-digit increase in the company’s bottom-line figure.

It’s been another eventful week in the markets. These three stocks just might add some more excitement for contrarian bulls.

McKesson has outperformed the Health Care Services industry over the past year, and analysts are highly optimistic about the stock’s prospects.

McKesson has outperformed the broader market over the past year, and Wall Street analysts maintain a highly optimistic outlook on the stock’s prospects.